Option Care Health’s (OPCH) Market Outperform Rating Reaffirmed at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Option Care Health (NASDAQ:OPCH) in a report published on Wednesday,Benzinga reports. JMP Securities currently has a $36.00 price target on the stock.

Several other equities analysts have also commented on OPCH. UBS Group upgraded Option Care Health from a “neutral” rating to a “buy” rating and raised their price target for the company from $38.00 to $40.00 in a research note on Wednesday, April 30th. Barrington Research restated an “outperform” rating and set a $38.00 price target on shares of Option Care Health in a research note on Wednesday, April 30th. Finally, JPMorgan Chase & Co. raised their price target on Option Care Health from $40.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $35.50.

Option Care Health Stock Down 0.9%

Shares of OPCH opened at $31.56 on Wednesday. The company has a market cap of $5.17 billion, a PE ratio of 25.45, a P/E/G ratio of 1.92 and a beta of 0.74. The business has a fifty day moving average of $32.12 and a 200 day moving average of $30.43. Option Care Health has a 52-week low of $21.39 and a 52-week high of $35.53. The company has a quick ratio of 1.02, a current ratio of 1.54 and a debt-to-equity ratio of 0.82.

Option Care Health (NASDAQ:OPCH) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Option Care Health had a return on equity of 16.90% and a net margin of 4.12%. The company had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period last year, the company earned $0.26 earnings per share. Option Care Health’s revenue was up 16.3% on a year-over-year basis. On average, sell-side analysts expect that Option Care Health will post 1.22 EPS for the current year.

Institutional Investors Weigh In On Option Care Health

Institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its holdings in shares of Option Care Health by 3.3% during the fourth quarter. Rhumbline Advisers now owns 564,518 shares of the company’s stock worth $13,097,000 after purchasing an additional 18,237 shares during the period. State of New Jersey Common Pension Fund D lifted its holdings in Option Care Health by 52.1% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 96,204 shares of the company’s stock valued at $2,232,000 after acquiring an additional 32,972 shares during the period. Principal Financial Group Inc. boosted its position in Option Care Health by 0.9% in the 4th quarter. Principal Financial Group Inc. now owns 479,255 shares of the company’s stock worth $11,119,000 after purchasing an additional 4,166 shares in the last quarter. Venturi Wealth Management LLC boosted its position in Option Care Health by 2,621.3% in the 4th quarter. Venturi Wealth Management LLC now owns 4,735 shares of the company’s stock worth $110,000 after purchasing an additional 4,561 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS boosted its position in Option Care Health by 2.5% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 444,095 shares of the company’s stock worth $10,303,000 after purchasing an additional 10,900 shares in the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.